2 Reasons to Buy Novavax Stock Now and 1 Reason to Skip It
It's been a harrowing quarter for Novavax (NASDAQ: NVAX) investors. The stock is down by more than 13% over the last three months, and even with approval for its coronavirus vaccine candidate seemingly in sight, it's reasonable to wonder whether the company's stock is worth purchasing.
Based on its upcoming catalysts, I think Novavax's losing streak will end before the close of 2021, and that rumors of its demise are exaggerated. Let's take a look at what I expect will be the two main drivers of the stock's near-term performance, and one caveat that investors need to take into account when they evaluate whether to buy it.
Image source: Getty Images.
Source Fool.com
